Date: 2014-09-15
Type of information: Nomination
Compound:
Company: Alnylam Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology - Rare diseases - Infectious diseases
Type agreement:
Action mechanism:
Disease:
Details: Alnylam Pharmaceuticals announced the expansion of its management team with the appointments of Karen Anderson as Senior Vice President, Chief Human Resources Officer; Laurie Keating as Senior Vice President, General Counsel, and Secretary; and Marko Kozul , M.D., as Vice President, Strategy. Karen Anderson comes to Alnylam from Biogen Idec where she served as Vice President, Human Resources for R&D and Corporate Development. Prior to Biogen Idec, Karen was the Vice President of Human Resources, Commercial for Pfizer Inc. covering both Developed Markets and Emerging Markets. Earlier in her 10-year tenure with Pfizer, Karen supported Worldwide R&D. Before joining Pfizer, Ms. Anderson spent 6 years at Baxter , most recently as Global Human Resources Director. Laurie Bartlett Keating joins Alnylam with more than 25 years of executive experience at high technology and biotechnology companies. Prior to joining Alnylam, Ms. Keating served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company\'s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Ms. Keating was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, Ms. Keating served as an executive at high growth technology companies, including serving as Senior Vice President, General Counsel and Secretary of Iomega Corporation , and Sybase, Inc. , a software company that grew from a few hundred to 6,000 employees during Ms. Keating\'s tenure on the management team. At Alnylam, Ms. Keating will lead the company\'s legal function, including corporate and intellectual property activities, and will lead the Alnylam\'s government affairs efforts. She will also serve as the Board secretary. Marko Kozul , M.D. comes to Alnylam from Leerink Partners where he served as a senior biotechnology analyst for 2 years. Prior to Leerink , he served as an analyst at ThinkEquity Partners for 2 years and Jefferies & Company for 5 years. Earlier in his career, he worked as the Research Director for Variant Medical Consulting Group and as a consultant for the Medical Referral Source, Inc. In this newly created role of Vice President, Strategy, Dr. Kozul will be responsible for the development of product strategy and portfolio management.
Financial terms:
Latest news:
